Nicola Deidre Petal Greenway Sells 12,980 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 12,980 shares of Takeda Pharmaceutical stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total value of $235,067.80. Following the completion of the transaction, the insider owned 40,049 shares in the company, valued at $725,287.39. This represents a 24.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Nicola Deidre Petal Greenway also recently made the following trade(s):

• On Monday, August 10th, Nicola Deidre Petal Greenway sold 6,774 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total transaction of $115,835.40.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $18.13 on Friday. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90. The business’s fifty day simple moving average is $16.75 and its 200-day simple moving average is $17.18. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The company has a market cap of $58.09 billion, a PE ratio of 53.32 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.17 by $0.30. The firm had revenue of $7.50 billion during the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Analysts expect that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA grew its holdings in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after purchasing an additional 783 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after buying an additional 1,684 shares in the last quarter. SHP Wealth Management acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $42,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Takeda Pharmaceutical by 313.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its position in Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.